MPH966
Pro00102362
Phase 2 small_molecule terminated
Quick answer
MPH966 for Hematologic Malignancy is a Phase 2 program (small_molecule) at Mereo BioPharma Group plc with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Mereo BioPharma Group plc
- Indication
- Hematologic Malignancy
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- terminated